Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma

Single antigen–targeted chimeric antigen receptor (CAR) T-cell therapy may be insufficient to induce a durable response in pediatric aggressive B-cell lymphomas. This clinical trial examined the feasibility of sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric relapsed/ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Deng, Biping, Hu, Bo, Zhang, Wenqun, Zhu, Qing, Liu, Yang, Wang, Shan, Zhang, Pei, Yang, Ying, Yang, Junhan, Zheng, Qinlong, Yu, Xinjian, Gao, Zifen, Zhou, Chunju, Han, Wei, Yang, Jing, Jin, Ling, Tong, Chunrong, Chang, Alex H., Zhang, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945318/
https://www.ncbi.nlm.nih.gov/pubmed/34521107
http://dx.doi.org/10.1182/bloodadvances.2021004557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945318/
https://www.ncbi.nlm.nih.gov/pubmed/34521107
http://dx.doi.org/10.1182/bloodadvances.2021004557

Ejemplares similares